Nexalin Technology (NXL)

• Market cap: $14.7M
• 1 day: 0.94%
• 5 days: 12.24%
• 1 month: -25.50%
• 3 months: -30.43%
• 6 months: -68.71%
• Year to date: -73.78%
• 1 year: -12.18%
• 5 years: -62.59%
• 10 years: -62.59%
• Sector: Healthcare
• Industry: Medical Devices

About: Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Employees: 7

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

70% more capital invested

Capital invested by funds: $775K [Q1] → $1.32M (+$545K) [Q2]

24% more funds holding

Funds holding: 17 [Q1] → 21 (+4) [Q2]

4.66% more ownership

Funds ownership: 2.99% [Q1] → 7.65% (+4.66%) [Q2]